Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2026-015063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Mario Mandalà und 44 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology, University of Perugia, Perugia, Italy mario.mandala@unipg.it. Hauptthemen laut MEDLINE: Melanoma, Brain Neoplasms, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH/NCI Cancer Center Support.
Abstract (Originalsprache)
Background
Nivolumab plus ipilimumab (COMBO) is the standard treatment for asymptomatic melanoma brain metastases (MBM), but current guidelines do not provide specific recommendations for treatment discontinuation in responding patients. This study aimed to evaluate outcomes after COMBO discontinuation within 24 months and the role of continuing treatment beyond 24 months.
Methods
Patients with MBM treated with COMBO who discontinued treatment within 24 months for reasons other than disease progression or continued beyond this time point were retrieved. Overall survival (OS), objective response, progression-free survival (PFS) and toxicities were analyzed.
Results
465 patients were included: 392 discontinued COMBO within 24 months, while 73 continued beyond 24 months. Treatment was discontinued due to complete response (CR, n=47), partial response (PR, n=45), stable disease (SD, n=12), toxicity after SD (n=59), toxicity after CR (n=99), or toxicity after PR (n=130). At multivariable analysis, the line of treatment (>first vs first: HR 2.65 (1.62–4.32)), the immune-related adverse events (irrespective of anti-tumor necrosis factor-alpha) (HR 0.18 (0.07–0.42)); COMBO discontinuation after CR (HR 0.15 (0.05–0.40)), or PR (HR 0.08 (0.03–0.26)), as well as stopping due to toxicity after CR (HR 0.14 (0.07–0.27)) or PR (HR 0.51 (0.32–0.82)), were associated with OS. Notably, at a median follow-up of 51 months (IQR 31–70), patients with CR/PR who discontinued COMBO within 24 months had PFS and OS comparable to those who continued treatment beyond this time point. 4-year OS exceeded 83% in patients discontinuing COMBO after CR, PR, or toxicity following CR, compared with 66.4% in those discontinuing due to toxicity after PR; median PFS was not reached in the former groups but was 18.6 months in the toxicity after PR group.
Conclusion
Discontinuation of COMBO within 24 months appears safe in patients with CR and in selected cases of PR, with no survival disadvantage versus prolonged therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Medical Oncology, University of Perugia, Perugia, Italy mario.mandala@unipg.it.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
- Mass General Brigham, Boston, Massachusetts, USA.
- San Paolo Hospital, Bari, Apulia, Italy.
- The Royal Marsden NHS Foundation Trust, London, UK.
Förderung
- NCI NIH HHS
- NIH/NCI Cancer Center Support
Zitieren
APA
Mandalà, M., Chen, M. F., Sullivan, R. J., Sergi, M. C., Postow, M., Lawless, A. R., Effiom, D., Peres, T., Lorigan, P. C., Serra-Bellver, P., Dummer, R., Amaral, T., Rasch, M. L., Giannarelli, D., Vitale, M. G., Helgadottir, H., Robert, C., Ubaldi, M., Johnson, D. B., …, & Ascierto, P. A. (2026). Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-015063
Vancouver
Mandalà M, Chen MF, Sullivan RJ, Sergi MC, Postow M, Lawless AR, et al. Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2026-015063
BibTeX
@article{Mandal2026,
author = {Mandalà, Mario and Chen, Monica F and Sullivan, Ryan J and Sergi, Maria Chiara and Postow, Michael and Lawless, Aleigha R and Effiom, Derek and Peres, Tobias and Lorigan, Paul C and Serra-Bellver, Patricio and Dummer, Reinhard and Amaral, Teresa and Rasch, Marie-Lena and Giannarelli, Diana and Vitale, Maria Grazia and Helgadottir, Hildur and Robert, Caroline and Ubaldi, Martina and Johnson, Douglas B and Del Vecchio, Michele and Indini, Alice and Suijkerbuijk, Karijn P M and Nathan, Paul and Carter, Thomas and Neyns, Bart and Dirven, Iris and Pires da Silva, Ines and Menzies, Alexander Maxwell and Zimmer, Lisa and Livingstone, Elisabeth and Depenni, Roberta and Kähler, Katharina and Hauschild, Axel and Spagnolo, Francesco and Di Giacomo, Anna Maria and Arance, Ana and Merelli, Barbara and Quaglino, Pietro and Rossi, Ernesto and Tucci, Marco and Guida, Michele and Muñoz-Couselo, Eva and Long, Georgina V and Larkin, James and Ascierto, Paolo A},
title = {Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2026-015063}
}
EUVIMED